What Causes Polycythemia Vera: The JAK2 Mutation

Polycythemia vera is driven by a single acquired mutation in the JAK2 gene, present in roughly 97% of all cases.¹ The mutation, known as V617F, flips a molecular switch inside blood-forming stem cells so that they churn out red blood cells, white blood cells, and platelets far beyond what the body needs. Understanding how one letter change in the genetic code produces a full-blown blood cancer sheds light on why the disease behaves the way it does, how it is diagnosed, and why newer therapies work.

How One Amino Acid Change Rewires Blood Cell Production

JAK2 is a signaling protein that normally sits on the inner surface of blood cell precursors, waiting for hormonal signals like erythropoietin (the hormone that tells the bone marrow to make red blood cells). When erythropoietin docks on the cell surface, JAK2 activates a chain of signals inside the cell that ultimately turns on genes for growth and survival. Once the hormone signal fades, JAK2 is supposed to quiet down. The V617F mutation breaks that off switch. The protein stays active all the time, flooding the cell with “grow and divide” signals regardless of whether the body actually needs more blood cells.²

The reason the mutation has such a dramatic effect comes down to internal architecture. JAK2 has two halves that look similar but do very different jobs. One half is the active enzyme that does the signaling work. The other half, sometimes called the pseudokinase domain, acts as a built-in brake, keeping the active half in check. Biochemical studies show this brake domain sharply reduces JAK2’s activity under normal conditions.³ The V617F mutation sits right in that brake domain and partially disables it, loosening the restraint on the active half. Structural studies have shown that the mutation stiffens a critical region of the brake domain, which makes it easier for the active half to switch on and stay on.⁴

The downstream effect is that bone marrow progenitor cells carrying V617F behave as though they are constantly receiving erythropoietin, even when actual erythropoietin levels are low or absent. Classic experiments on blood cells from PV patients demonstrated that some progenitor cells could form red blood cell colonies in the lab without any added erythropoietin at all, something healthy progenitors cannot do.⁵ This erythropoietin-independent colony growth has long been a hallmark of PV and is now understood as a direct consequence of constitutively active JAK2 signaling. In one study of PV patients carrying the V617F mutation, 98% showed this kind of autonomous colony formation.⁶

The Exon 12 Mutations

About 3% of PV patients do not carry V617F. Almost all of them turn out to have a different set of mutations in the same gene, located in a region called exon 12. In 2007, researchers identified four distinct gain-of-function mutations in exon 12 among patients who had been classified as V617F-negative. These patients typically presented with an isolated rise in red blood cells rather than the broad increase in red cells, white cells, and platelets seen in most V617F-positive cases.⁷ Subsequent studies confirmed these findings, identifying additional exon 12 variants and noting that the most common types involve small deletions in the same stretch of the gene.⁸

Bone marrow biopsies from exon 12 patients tend to show heavy red cell overproduction as the dominant feature, sometimes with abnormal platelet-producing cells and early scarring as well.⁹ In a large observational study of over 2,500 PV patients in the United States, fewer than 1% tested positive for exon 12 mutations, compared with about 96% who were V617F-positive.¹⁰ The practical takeaway is that virtually every PV case traces back to an activating mutation in JAK2, whether in V617F or exon 12.

Why Some People Develop the Mutation

JAK2 V617F is not inherited in a simple sense. It is a somatic mutation, meaning it arises spontaneously in a blood stem cell during a person’s lifetime rather than being passed down from a parent. Yet not everyone is equally likely to acquire it. Research has identified an inherited background called the 46/1 haplotype (also called the GGCC haplotype), a specific pattern of common genetic variants in and around the JAK2 gene region. People who carry this haplotype develop JAK2-mutant blood cancers at higher rates than those who do not.¹¹

A study that genotyped 149 patients with myeloproliferative neoplasms and 150 healthy controls found that a key marker of the 46/1 haplotype was significantly enriched in patients compared to controls. Strikingly, the enrichment was concentrated among patients who actually carried the V617F mutation; V617F-negative patients showed no significant difference from controls.¹² The same study found the haplotype was also linked to higher mutant allele burdens, meaning more of the patient’s blood cells had switched over to carrying the mutation. Why the 46/1 haplotype makes the V617F mutation more likely to occur or more likely to take hold once it does is still debated, but the association is one of the strongest and most replicated findings in the field.

From One Mutant Cell to a Blood Disease

The V617F mutation typically starts in a single blood stem cell. That cell has a growth advantage over its normal neighbors because it no longer waits for erythropoietin to tell it to divide. Over months or years, the mutant cell’s descendants crowd out normal blood production, a process called clonal expansion. In many PV patients, the mutation goes a step further. A chromosomal copying error called uniparental disomy of chromosome 9p causes the cell to lose its normal copy of JAK2 and replace it with a second copy of the mutant version. The result is that both copies of the gene are now V617F, doubling the signaling intensity. This homozygous state is associated with more aggressive disease and less favorable outcomes.¹³

JAK2 mutations rarely act alone for the full course of the disease. Since 2005, when V617F was first identified in PV patients, gene discovery efforts have uncovered additional mutations in genes like TET2 and ASXL1 that can appear before or after the JAK2 mutation.¹⁴ These additional hits do not cause PV on their own, but they influence how the disease evolves. For instance, ASXL1 mutations have been linked to accelerated progression from PV into myelofibrosis, a condition in which scar tissue gradually replaces healthy bone marrow.¹⁵ In a small fraction of patients, continued accumulation of mutations can push the disease toward acute myeloid leukemia. A prognostic model found that patients with elevated blast counts and unfavorable chromosome changes had a median survival of only 10 months.¹⁶

Why PV Raises the Risk of Blood Clots

The most dangerous immediate consequence of PV is thrombosis. The excess red blood cells thicken the blood, increasing viscosity and making clots more likely. Microvascular problems like erythromelalgia (painful burning and redness in the hands and feet), transient visual disturbances, and atypical strokes are directly related to the elevated red cell mass and the resulting increase in blood viscosity.¹⁷

But red cell overproduction is not the only driver. Data from the REVEAL study, a prospective observational study of over 2,500 PV patients in the United States, showed that a hematocrit above 45% roughly doubled the risk of a thrombotic event. Equally important, white blood cell counts above a certain threshold independently raised the risk even when hematocrit was controlled. Among patients whose hematocrit was kept at or below 45%, those with elevated white cell counts still had about twice the hazard of thrombosis compared to those with lower counts.¹⁸ Other established risk factors include older age, a history of prior clots, cardiovascular risk factors for arterial events, and higher JAK2 V617F allele burden for venous events.¹⁹

How PV Is Diagnosed

Most patients first come to attention through a routine blood test that reveals unusually high hemoglobin or hematocrit. In the REVEAL study, about 90% of patients were diagnosed after an abnormal blood test rather than after symptoms prompted investigation.¹⁰ World Health Organization diagnostic criteria rely on hemoglobin and hematocrit thresholds as practical stand-ins for the more cumbersome measurement of total red cell mass, combined with bone marrow biopsy findings and the presence of the JAK2 mutation.²⁰

Distinguishing PV from secondary causes of high red blood cell counts, like chronic lung disease, sleep apnea, or living at high altitude, matters because the treatment is completely different. JAK2 mutation testing is the single most useful discriminator, but other lab markers have also proven helpful. One study found that measuring expression of a gene called PRV-1 in white blood cells cleanly separated PV patients from those with secondary erythrocytosis, with no overlap between the two groups.²¹ In practice, a positive JAK2 V617F or exon 12 test in the right clinical setting is usually sufficient to confirm the diagnosis.

Treatments That Target JAK2 Signaling

For decades, the main treatments for PV were phlebotomy (periodically drawing blood to lower the red cell count) and low-dose aspirin to reduce clot risk. These remain foundational, but phlebotomy does nothing to rein in the overactive JAK2 signaling or reduce elevated white cell and platelet counts. The microvascular circulation problems driven by high platelet counts persist even after phlebotomy brings hematocrit down.¹⁷

Ruxolitinib, a drug specifically designed to block JAK1 and JAK2, became the first targeted therapy approved for PV. In cell lines carrying V617F, ruxolitinib shut down the signals downstream of JAK2 and triggered cell death in a dose-dependent fashion.²² In a randomized trial of PV patients who were resistant to or intolerant of their prior treatment, ruxolitinib controlled hematocrit in about 60% of patients compared with 20% on standard therapy, and nearly half the ruxolitinib group experienced at least a 50% reduction in symptom burden, compared with 5% in the control group.²³ Ruxolitinib is effective at controlling symptoms and blood counts, but it does not eliminate the mutant clone in most patients.

Interferon-based therapies, particularly a long-acting formulation called ropeginterferon alfa-2b, take a different approach. Rather than just blocking the JAK2 signal, interferon appears to selectively suppress the mutant stem cells over time. A meta-analysis of ropeginterferon studies found a statistically significant reduction in JAK2 V617F allele burden during treatment.²⁴ A real-world analysis of interferon-treated patients showed a median drop in the mutant allele fraction from 28% to about 4%, with roughly 80% of patients achieving at least a 50% reduction and about 5% reaching undetectable levels.²⁵ Whether driving down the mutant clone translates into long-term disease modification and reduced risk of progression to myelofibrosis or leukemia is a question researchers are still tracking over years of follow-up.

Who Gets PV and at What Age

PV is rare but not vanishingly so. Recent estimates from German health claims data put the incidence at about 3.3 new cases per 100,000 adults per year and the prevalence at roughly 29 per 100,000.²⁶ A long-running Swedish study found rising incidence rates over several decades, probably due to better detection rather than a true increase in the disease, with the highest rates in men over 80 and women in their 70s.²⁷ The median age at diagnosis in the REVEAL cohort was 67 years, with a slight male predominance.¹⁰

PV can occur in children, though it is exceptionally uncommon and poses unique diagnostic challenges. The JAK2 V617F mutation, so ubiquitous in adult PV, is found far less consistently in pediatric cases. A review of myeloproliferative neoplasms in children noted that the hallmark driver mutations of adult disease rarely occur in pediatric patients, which makes diagnosis harder when there is no clear clonal marker to confirm the disease.²⁸ A French study that collected data on 17 children with myeloproliferative neoplasms found that among the two who had PV, both carried V617F, but across the broader group including essential thrombocythemia, 59% were “triple negative,” lacking mutations in JAK2, CALR, or MPL.²⁹ These cases suggest that in children, alternative and still poorly understood mechanisms may drive the disease.

The Bone Marrow Neighborhood

The JAK2 mutation does not operate in isolation from the bone marrow environment. The marrow is not just a factory floor where blood cells are made; it is a complex ecosystem of support cells, blood vessels, and signaling molecules that influence which cells thrive and which do not. Research into the stromal cells that form the scaffolding of the bone marrow has found that in PV patients, these support cells themselves develop an altered secretory profile. They release signals that promote new blood vessel growth, shift immune cell behavior, and change how cells communicate within the marrow, collectively fostering an environment that favors the mutant clone.³⁰ Whether these stromal changes are caused by the mutant blood cells or develop independently and then help sustain the disease is an active area of investigation. Either way, it means that PV is not simply a problem of one rogue gene in one cell line. The broader bone marrow neighborhood is remodeled in ways that may help explain why the disease is hard to eradicate completely, even with treatments that substantially reduce the mutant clone.